MedPage Today on MSN
PD-1 Inhibitor Raises PFS in Advanced Acral Melanoma
First-line treatment of advanced acral melanoma with the PD-1 inhibitor toripalimab (Loqtorzi) resulted in a small but ...
The FDA approved the PD-1 inhibitor penpulimab, with two indications, for treating non-keratinizing nasopharyngeal carcinoma (NPC) in adults. No trade name was indicated for the drug. The first ...
A multinational collaboration co-led by the Garvan Institute of Medical Research has uncovered a potential explanation for why some cancer patients receiving a type of immunotherapy called checkpoint ...
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that Akeso, Inc. (Akeso, HKEX Code: 9926.HK) announced that the Phase III clinical trial, ...
Hosted on MSN
Regeneron says FDA approves PD-1 inhibitor Libtayo
Regeneron (REGN) Pharmaceuticals announced that the U.S. Food and Drug Administration has approved the PD-1 inhibitor Libtayo as an adjuvant treatment for adult patients with cutaneous squamous cell ...
Researchers at the University of Sharjah are exploring a promising approach that could enhance the immune system's ability to ...
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced it has entered into a collaboration and supply agreement with BeiGene, Ltd. (to be changed to BeOne Medicines, ...
SEATTLE, WASHINGTON / ACCESS Newswire / May 8, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback